Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer

Molecular Imaging and Biology

Volumn 12, Issue 3, 2010, Pages 349-358

  Wyatt, Shelby K ^a,b   Hcharles, Manning ^a,b,c,d,e   Bai, Mingfeng ^f   Bailey, Stephanie N ^f   Gallant, Pascal ^g   Ma, Guobin ^g   McIntosh, Laura ^g   Bornhop, Darryl J ^a,d,e,f  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g ART Advanced Research Technologies Inc   (Canada)

Author keywords

Breast cancer; Diagnosis; MDA MB 231; Molecular imaging; Peripheral benzodiazepine receptor; PK 11195; Prognosis; Staging; Steroidogenesis; Translocator protein

Indexed keywords

CARRIER PROTEIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; 4 AMINOBUTYRIC ACID RECEPTOR; TSPO PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; BIOACCUMULATION; BREAST ADENOCARCINOMA; CARCINOMA CELL; CELL LABELING; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; FLUORESCENCE MICROSCOPY; METABOLISM; METHODOLOGY; MOLECULAR PROBE; NEAR INFRARED SPECTROSCOPY; PATHOLOGY; TIME; TISSUE DISTRIBUTION; TUMOR CELL LINE; WHOLE BODY IMAGING;

MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; MOLECULAR IMAGING; MOLECULAR PROBES; RECEPTORS, GABA; SPECTROSCOPY, NEAR-INFRARED; TIME FACTORS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 77956671187     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0270-8     Document Type: Article

References (54)

1. American Cancer Society (2009) Cancer Facts and Figures. Atlanta: American Cancer Society
2. Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. JAMA 293(10):1245-1256
3. Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168-175
4. DeMartini W, Lehman C, Partridge S (2008) Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications. Acad Radiol 15(4):408-416
5. Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA (1995) Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 196(1):123-134
6. Bremer C, Ntziachristos V, Weissleder R (2003) Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol 13(2):231-243
7. Cerussi A, Shah N, Hsiang D, Durkin A, Butler J, Tromberg BJ (2006) In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy. J Biomed Opt 11(4)
8. Godavarty A, Thompson AB, Roy R et al (2004) Diagnostic imaging of breast cancer using fluorescence-enhanced optical tomography: phantom studies. J Biomed Opt 9(3):488-496
9. Intes X (2005) Time-domain optical mammography SoftScan: Initial results. Acad Radiol 12(8):934-947
10. Ntziachristos V, Chance B (2001) Probing physiology and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res 3(1):41-46
11. Ntziachristos V, Yodh AG, Schnall M, Chance B (2000) Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A 97(6):2767-2772
12. Tromberg BJ, Cerussi A, Shah N et al (2005) Imaging in breast cancer- diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 7(6):279-285
13. Kaijzel EL, van der Pluijm G, Lowik CWGM (2007) Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res 13(12):3490-3497
14. Luker GD, Luker KE (2008) Optical imaging: current applications and future directions. J Nucl Med 49(1):1-4
15. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS (2007) Molecular imaging techniques in body imaging. Radiology 245(2):333-356
16. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46(7):1144-1150
17. Schelling M, Avril N, Nahrig J et al (2000) Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18(8):1689-1695
18. Smith IC, Welch AE, Hutcheon AW et al (2000) Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18(8):1676-1688
19. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11(11):2101-2111
20. Been LB, Elsinga PH, de Vries J et al (2006) Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l- thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 32(1):39-43
21. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'- deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34(9):1339-1347
22. Pio BS, Park CK, Pietras R et al (2006) Usefulness of 3'-[F-18]fluoro- 3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8(1):36-42
23. Smyczek-Gargya B, Fersis N, Dittmann H et al (2004) PET with [18F] fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31(5):720-724
24. Jonson SD,Welch MJ (1998) PET imaging of breast cancer with fluorine- 18 radiolabeled estrogens and progestins. Q J Nucl Med 42(1):8-17
25. Linden HM, Stekhova SA, Link JM et al (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24(18): 2793-2799
26. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA (2008) Tumor receptor imaging. J Nucl Med 49:149S-163S
27. Mankoff DA (2006) Radiotracer breast cancer imaging: beyond FDG and MIBI. Phys Med 21(Suppl 1):12-16
28. Pantaleo MA, Nannini M, Maleddu A et al (2008) Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 34(2):103-121
29. Quon A, Gambhir SS (2005) FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 23(8):1664-1673
30. Papadopoulos V, Baraldi M, Guilarte TR et al (2006) Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27(8):402-409
31. Black KL, Ikezaki K, Toga AW (1989) Imaging of brain tumors using peripheral benzodiazepine receptor ligands. J Neurosurg 71(1):113-118
32. Han Z, Slack RS, Li W, Papadopoulos V (2003) Expression of Peripheral Benzodiazepine Receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct. 23(2-3):225-238
33. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V (1999) Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 59 (4):831-842
34. Hardwick M, Rone J, Han Z, Haddad B, Papadopoulos V (2001) Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice. Int J Cancer 94(3):322-327
35. Maaser K, Grabowski P, Sutter AP et al (2002) Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer. Clin Cancer Res 8(10):3205-3209
36. Starosta-Rubinstein S, Ciliax BJ, Penney JB, McKeever P, Young AB (1987) Imaging of a glioma using peripheral benzodiazepine receptor ligands. Proc Natl Acad Sci U S A 84(3):891-895
37. Venneti S, Lopresti BJ, Wiley CA (2006) The peripheral benzodiazepine receptor (Translocator protein 18 kDa) in microglia: from pathology to imaging. Prog Neurobiol 80(6):308-322
38. Deane NG, Manning HC, Foutch AC et al (2007) Targeted imaging of colonic tumors in smad3?/? mice discriminates cancer and inflammation. Mol Cancer Res 5(4):341-349
39. Manning HC, Goebel T, Marx JN, Bornhop DJ (2002) Facile, efficient conjugation of a trifunctional lanthanide chelate to a peripheral benzodiazepine receptor ligand. Org Lett 4(7):1075-1078
40. Ma G, Gallant P, McIntosh L (2007) Sensitivity characterization of a time-domain fluorescence imager: eXplore Optix. Appl Opt 46 (10):1650-1657
41. Bai M, Wyatt SK, Han Z, Papadopoulos V, Bornhop DJ (2007) A novel conjugable translocator protein ligand labeled with a fluorescence dye for in vitro imaging. Bioconjug Chem 18(4):1118-1122
42. Kozikowski AP, Kotoula M, Ma D, Boujrad N, Tuckmantel W, Papadopoulos V (1997) Synthesis and biology of a 7-nitro-2,1,3- benzoxadiazol-4-yl derivative of 2-phenylindole-3-acetamide: a fluorescent probe for the peripheral-type benzodiazepine receptor. J Med Chem 40(16):2435-2439
43. Manning HC, Goebel T, Thompson RC, Price RR, Lee H, Bornhop DJ (2004) Targeted molecular imaging agents for cellular-scale bimodal imaging. Bioconjug Chem 15(6):1488-1495
44. Manning HC, Smith SM, Sexton M et al (2006) A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening. Bioconjug Chem 17(3):735-740
45. Taliani S, Simorini F, Sergianni V et al (2007) New fluorescent 2- phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation. J Med Chem 50(2):404-407
46. Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11(17-18):812-818
47. Bai M, Rone MB, Papadopoulos V, Bornhop DJ (2007) A novel functional translocator protein ligand for cancer imaging. Bioconjug Chem 18(6):2018-2023
48. Benavides J, Quarteronet D, Imbault F et al (1983) Labelling of "peripheral-type" benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem 41(6):1744-1750
49. Chaki S, Funakoshi T, Yoshikawa R et al (1999) Binding characteristics of [3H]DAA1106, a novel and selective ligand for peripheral benzodiazepine receptors. Eur J Pharmacol 371(2-3):197-204
50. Ferzaz B, Brault E, Bourliaud G et al (2002) SSR180575 (7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]i ndole- 1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J Pharmacol Exp Ther 301(3):1067-1078
51. Newman AH, Lueddens HW, Skolnick P, Rice KC (1987) Novel irreversible ligands specific for "peripheral" type benzodiazepine receptors: (+/?)-, (+)-, and (?)-1-(2-chlorophenyl)-N-(1-methylpropyl)-N- (2-isothiocyanatoethyl)- 3-isoquinolinecarboxamide and 1-(2-isothiocyanatoethyl) -7- chloro-1,3-dihydro-5-(4-chlorophenyl )-2H-1,4-benzodiazepin-2-one. J Med Chem 30(10):1901-1905
52. Okuyama S, Chaki S, Yoshikawa R et al (1999) Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sci 64(16):1455-1464
53. Romeo E, Auta J, Kozikowski AP et al (1992) 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J Pharmacol Exp Ther 262(3):971-978
54. Vin V, Leducq N, Bono F, Herbert JM (2003) Binding characteristics of SSR180575, a potent and selective peripheral benzodiazepine ligand. Biochem Biophys Res Commun 310(3):785-790